• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Bernards Rene bought $24,116 worth of shares (10,000 units at $2.41), increasing direct ownership by 33% to 20,000 units (SEC Form 4)

    10/4/23 6:10:01 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LIXT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Bernards Rene

    (Last) (First) (Middle)
    KONINGSVAREN 37

    (Street)
    ABCOUDE P7 1391AD

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    LIXTE BIOTECHNOLOGY HOLDINGS, INC. [ LIXT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    10/02/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 10/02/2023 P 4,473 A $2.29 $19,472(1) D
    Common Stock 10/03/2023 P 5,527 A $2.51 $20,000(2) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The Reporting Person acquired an aggregate of 4,473 shares in numerous trades at prices ranging from $2.29-$2.40
    2. The Reporting Person acquired an aggregate of 5,527 shares in numerous trades ranging from $2.51-$2.58
    /s/ Rene Bernards 10/04/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LIXT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LIXT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LIXT
    SEC Filings

    View All

    Lixte Biotechnology Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)

    12/11/25 2:51:47 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lixte Biotechnology Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)

    11/25/25 5:00:24 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Lixte Biotechnology Holdings Inc.

    10-Q - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)

    11/12/25 4:26:01 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Bernards Rene bought $24,116 worth of shares (10,000 units at $2.41), increasing direct ownership by 67% to 25,000 units (SEC Form 4) (Amendment)

    4/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    10/5/23 8:39:03 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Van Der Baan Bastiaan Jeroen bought $28,000 worth of shares (10,000 units at $2.80), increasing direct ownership by 1,000% to 11,000 units (SEC Form 4)

    4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    10/5/23 8:36:30 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bernards Rene bought $24,116 worth of shares (10,000 units at $2.41), increasing direct ownership by 33% to 20,000 units (SEC Form 4)

    4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    10/4/23 6:10:01 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment

    Located at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million invested to date in developing the technology BOCA RATON, Fla., Nov. 25, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT) a biotech company focused on advancing cancer treatments, today announced it has completed the acquisition of Liora Technologies Europe Ltd., a UK-based company pioneering electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora will become a wholly owned subsidiary of LIXTE. The acquisition includes Liora's proprietary flagship technology LiGHT Sys

    11/25/25 8:30:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3

    BOCA RATON, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT, LIXTW)), a clinical-stage pharmaceutical company advancing LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A), today announced that Geordan Pursglove, its chief executive officer, will present at the Spartan Capital Investor Conference 2025 in New York, on November 3, 2025, at 4 p.m. ET. Management will conduct one-on-one meetings with investors during the conference. The conference will be held at the Marriott Marquis Hotel, 1535 Broadway. To register or schedule a one-on-one meeting, please visit https://spartancapital.com/spartan-capital-inves

    10/29/25 8:00:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans

    Company underscores clinical execution and confirms advanced negotiations underway on acquisition of complementary oncology assets BOCA RATON, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT, LIXTW)), a clinical-stage pharmaceutical company advancing LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A), today outlined its fourth-quarter 2025 priorities and provided an update on its strategic business development and acquisition initiatives focused on oncology. "LIXTE is entering Q4 with clear operational goals and a disciplined approach to strategic expansion," said Geordan Pursglove, Chairman and Chief Exe

    10/16/25 8:00:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Primus Guy Warren

    3 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    9/10/25 2:20:02 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Stazzone Peter

    4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    9/4/25 2:58:31 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Stazzone Peter

    3 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    9/4/25 1:53:27 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Financials

    Live finance-specific insights

    View All

    LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment

    Located at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million invested to date in developing the technology BOCA RATON, Fla., Nov. 25, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT) a biotech company focused on advancing cancer treatments, today announced it has completed the acquisition of Liora Technologies Europe Ltd., a UK-based company pioneering electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora will become a wholly owned subsidiary of LIXTE. The acquisition includes Liora's proprietary flagship technology LiGHT Sys

    11/25/25 8:30:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Leadership Updates

    Live Leadership Updates

    View All

    LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

    -- Company Relocates Corporate Headquarters to Boca Raton -- Boca Raton, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced that Lourdes Felix and Guy Primus have joined the Company's Board of Directors, and Peter Stazzone has been named Chief Financial Officer. The Company also announced that it has relocated its corporate headquarters to Boca Raton. The new board members succeed Bas van der Baan, who remains Chief Scientific Officer of LIXTE, and René Bernards, PhD, who has been n

    9/3/25 8:00:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

    PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced the appointment of Jan Schellens, M.D., Ph.D., as Chief Medical Officer (CMO). Dr. Schellens brings to LIXTE more than 25 years of clinical experience as a medical oncologist, pharmacologist and clinical pharmacologist, including more than two decades developing and bringing new drugs to market. He assumes the CMO role at LIXTE effective August 1, 2024, succeeding James S. Miser, M.D., who is leaving the Company after serv

    6/3/24 8:30:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

    Biotechnology Veteran Bas van der Baan Brings Precision Oncology Expertise; Founder John S. Kovach Named Executive Chairman PASADENA, CA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, announced that Bas van der Baan has been named as President and Chief Executive Officer of the Company, and as Vice Chairman of the Board of Directors, effective as of September 26, 2023. He has been a member of LIXTE'S Board of Directors since June 2022. Mr. van der Baan succeeds John S. Kovach, M.D., 87, who founded the Company in 2005 a

    9/26/23 8:30:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Lixte Biotechnology Holdings Inc.

    SC 13G - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)

    4/6/22 9:58:22 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Lixte Biotechnology Holdings Inc. (Amendment)

    SC 13G/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)

    4/6/22 9:59:12 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed

    SC 13G - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)

    3/3/21 7:45:27 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care